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henotypic Heterogeneity of
arcomeric Gene Mutations
Matter of Gain and Loss?*
uisa Mestroni, MD
urora, Colorado; and Trieste, Italy
fter several decades of intense research and various at-
empts at definition and classification, cardiomyopathies
till remain disorders of remarkable and intriguing complex-
ty. Once more, this aspect is elicited by the recent discovery
hat mutations in the cardiac ankyrin repeat protein
CARP), a protein functionally part of the sarcomere, can
ause different types of cardiomyopathies, as reported by
oulik et al. (1) and Arimura et al. (2) in this issue of the
ournal, as well as congenital heart disease (3).
See pages 325 and 334
NKRD1 in normal heart and disease. CARP is a 36 kD
rotein encoded by the cardiac ankyrin repeat domain 1
ene ANKRD1, which maps on chromosome 10. ANKRD1
s a member of a conserved gene family, coding for muscle
nkyrin repeat proteins (MARPs), involved in muscle stress
esponse such as stretch, injury, and hypertrophy (4). CARP
s a nuclear transcription cofactor, a signaling molecule
redominantly expressed in the heart. CARP is found in the
arcomere, where it colocalizes with the N2A domain of
itin and myopalladin in the I-band of the Z disk (Fig. 1),
nd in the nucleus (4). The expression of CARP is con-
rolled, at least in part, by the titin-based mechanotrans-
uction signaling pathway, and it is increased in heart
evelopment and conditions of injury and stress. In heart
evelopment, CARP acts as a transcriptional repressor of
yocyte contractile elements. In heart failure, CARP is
verexpressed, suggesting a role in the “fetal gene program”
haracteristic of the molecular remodeling of the failing
eart (5).
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the University of Colorado Cardiovascular Institute and Adult Medical
enetics Program, University of Colorado at Denver and Health Sciences Center,
urora, Colorado; and Cluster in BioMedicine, Trieste, Italy. Supported by thev
ational Institutes of Health (HL69071-01, MO1 RR00051-1575), American Heart
ssociation 0150453N, and Muscular Dystrophy Association PN0007-056.Because titin was previously found to be associated with
oth hypertrophic cardiomyopathy (HCM) and dilated
ardiomyopathy (DCM) (6–8), CARP, as part of the titin
omplex, was also hypothesized to play a role in cardiomy-
pathies. In this issue of the Journal, 2 reports (1,2) confirm
his hypothesis and show that in fact ANKRD1 mutations
an cause both DCM and HCM.
Arimura et al. (2) report the results of the ANKRD1
utation screening in a large HCM population collected in
apan and in the U.S. In 384 index patients, they found 3
issense mutations (ANKRD1 Pro52Ala, Thr123Met, and
le280Val), accounting for 1% of HCM cases. Interest-
ngly, they also investigated the N2A CARP-binding do-
ain of titin, and found 2 additional mutations (TTN
rg8500 and Arg8604Gln) in their HCM cohort. Moulik
t al. (1) investigated a series of 208 DCM index patients of
apanese and U.S. origin, and found 3 missense mutations
ANKRD1 Pro105Ser, which was recurrent in 2 families,
al107Leu, and Met1841Ile) accounting for 2% of DCM
ases, further supporting a role of the titin mechanotrans-
uction complex in the pathogenesis of cardiomyopathies.
ut how to explain 2 different cardiomyopathies with
pposite pathophysiology caused by the same gene?
henotypic heterogeneity in cardiomyopathies. Pheno-
ypic heterogeneity (also called “allelic variants” in OMIM)
9) is a well-known and common phenomenon in genetics,
eferring to the occurrence of more than 1 phenotype caused
y allelic mutations at a single locus (10); examples familiar
o cardiologists are Duchenne and Becher muscular dystro-
hies caused by the same dystrophin gene, laminopathies
anging from progeria to lipodystrophy due to lamin A/C
ene, and LQT syndrome and congenital conduction defect
aused by the cardiac sodium channel gene SCN5A.
The reason for the clinical variability in allelic disorders
ies in the different function of the mutant proteins. In the
ase of sarcomeric genes, it appears that a “gain” of function
sually results in increased energy demand, inefficient aden-
sine triphosphate utilization, and hypertrophy, whereas a
loss” of function results in decreased contractility (Table 1).
he 2 studies published in this issue seem to follow the rule.
rimura et al. (2) show that ANKRD1 mutations in HCM
ncrease binding of CARP to titin and myopalladin, and
hat titin mutations at the CARP-binding site have the
ame effect. Conversely, Moulik et al. (1) show that
NKRD1 mutations in DCM cause a loss of CARP
inding to talin 1, potentially leading to loss of stretch-
ensing, disruption of the link between titin complex and
ytoskeletal network, and transcriptional deregulation of
enes involved in cell cycle and other pathways.
However, gain and loss are not the only mechanisms
nvolved in the phenotypic heterogeneity of ANKRD1.
ndeed, a recent publication by Cinquetti et al. (3) reports
he identification of increased CARP expression or pro-
ein stability in 3 cases with total anomalous pulmonary
enous return, a rare congenital heart defect characterized
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ANKRD1 and Heart Disease July 21, 2009:343–5y failure of the pulmonary veins to connect to the left
trium during development. In this case, CARP overex-
ression or its increased activity are believed to repress
ormal cardiac gene expression, leading to abnormal
eart development.
mpact of ANKRD1 mutations discovery in clinical
are. The discovery of ANKRD1 mutations in cardiomy-
pathies has several implications. First, it contributes to fill
he gap of the large number of patients in whom the cause
f cardiomyopathy is still unknown, 40% of cases in
CM and probably 70% in DCM (11). Second, it
xpands our knowledge of the mechanisms leading to
ypertrophy and heart failure to include abnormal stretch-
ased signaling in response to force: this appears to be
nother “common pathway” for HCM and DCM that could
e targeted by novel therapeutic strategies. Finally, it raises
he question of clinical genetic testing of ANKRD1 in
CM and DCM patients. Although the low prevalence of
utations may currently limit routine screening for the
NKRD1 gene, we may expect that the implementation of
esequencing technology will allow a systematic screening
or rare cardiomyopathy genes in these patients in the near
Figure 1 Model for the Titin-N2A Signaling Complex
The sequence of N2A titin interacts with muscle ankyrin repeat proteins (MARP
ankyrin repeat protein. Myopalladin associates with the MARP/N2A complex by
noglobulin; IS  muscle specific sequence; NH2  N-terminal domain; PEVK 
residues. Reprinted with permission from Miller et al. (4).uture.eprint requests and correspondence: Dr. Luisa Mestroni,
olecular Genetics, CUCVI, 12700 East 19th Avenue, Mail Stop
442, Aurora, Colorado 80045-6511. E-mail: Luisa.Mestroni@
cdenver.edu.
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Thick filament
MYH7 Cardiac myosin heavy
chain
Yes 2Maximal force g
2Contractility
2Velocity of actin
MYH6 Cardiac myosin heavy
chain
Yes *
MYL2 Regulatory myosin light
chain
Not described
MYL3 Essential myosin light
chain
Not described
MYBPC3 Cardiac myosin-binding
protein C
Yes
Thin filament
TNNT2 Cardiac troponin T Yes 2Myofibrillar funct
2Ca sensitivity
TNNTI3 Cardiac troponin I Yes 2Myofibrillar funct
2Binding to cTnT
TNNC1 Cardiac troponin C Yes 2Myofibrillar funct
2Ca sensitivity
2PKC effect
TPM1 Tropomyosin 1  chain Yes 2Ca sensitivity
2Maximum force
ACTC1 -cardiac actin Yes 2-Cardiac actinin
affinity
2Force transmissio
Titin filament and Z-disk
TTN Titin Yes 2Binding to actinin
Tcap
TCAP Titin-cap or telethonin Yes 2Binding to titin, M
myozenin-2
ANKRD1 Cardiac ankyrin repeat
protein
Yes 2Binding to talin1
LDB3 Cypher/ZASP Yes Cytoskeletal disarra
2PKC affinity
CSRP3 MLP Yes
MYOZ2 Myozenin-2 Not described
OBSCN Obscurin Not described
ata from Matsumoto et al. (8), McKusick (9), Mizra et al. (12), Kaski et al. (13), Debold et al. (
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5. Rajan S, Ahmed RP, Jagatheesan G, et al. Dilated cardiomyopathy
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of Mutant Protein Functiontial Changes of Mutant Protein Function
HCM Function Other Allelic Disorders
ion Yes 1Maximal force
generation
1Ca sensitivity
Laing distal myopathy, myosin
storage myopathy,
scapuloperoneal myopathy,
left ventricular noncompaction,
endocardial fibroelastosis
Yes * Atrial septal defect
Yes 1Ca sensitivity
Yes 1Ca sensitivity
Yes Hypertrophy diastolic
dysfunction
Yes 1Myofibrillar function Restrictive cardiomyopathy
1Ca sensitivity
Yes 1Myofibrillar function Restrictive cardiomyopathy
1Ca sensitivity (_Ca sensitivity)
Yes 1Myofibrillar function
Yes 1Myofibrillar function
1Ca sensitivity
) Yes Impaired actomyosin
binding
Restrictive cardiomyopathy
Yes 1Binding to actinin and
Tcap
Tibialis muscular dystrophy or Udd
distal myopathy; hereditary
myopathy with early respiratory
failure; recessive limb-girdle
muscular dystrophy type 2J
d Yes 1Binding to titin and
myozenin-2
Limb-girdle muscular dystrophy
type 2G
Yes 1Binding to titin and
myopalladin
Total anomalous pulmonary venous
return (1expression)
Not described Left ventricular noncompaction,
myofibrillar myopathy
Yes 2Binding to actinin
Yes
Yes 2Binding to titin
jan et al. (15), and Morimoto (16). *The  myosin heavy chain mutations found in hypertrophic
k-in mouse models.
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